Iovance Biotherapeutics (IOVA)
(Real Time Quote from BATS)
$10.51 USD
+0.16 (1.55%)
Updated May 21, 2024 10:15 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Iovance Biotherapeutics, Inc. [IOVA]
Reports for Purchase
Showing records 121 - 140 ( 180 total )
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Password Remains Consistency as First BLA Filing Rapidly Approaches
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; Looking Towards First Two BLAs;
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moffitt AACR Data Continue to Solidify Targeting NSCLC; Target Increased to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department